Parametric Portfolio Associates’s Dyne Therapeutics DYN Stock Holding History

Parametric Portfolio Associates’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$97K	Buy	+10,113	New	+$86.1K	﹤0.01%	3567

Other funds holding DYN

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Parametric Portfolio Associates's DYN Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Dyne Therapeutics (DYN) in Q1 2022: 10,113 shares worth $97K. The stake represents ﹤0.01% of the portfolio and ranks #3567 among its holdings.

95 funds tracked by Wall St. Rank hold DYN as of Q1 2022.

Parametric Portfolio Associates held 10,113 shares of Dyne Therapeutics worth $97K as of Q1 2022.
Dyne Therapeutics was a new Parametric Portfolio Associates position in Q1 2022.
Dyne Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3567 holding.
95 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.